Skip to main contentSkip to navigationSkip to search

Japanese patent application 2019-005811 is accepted for grant

December 16, 2020


The Japan Patent Office has issued a notice of allowance confirming that the Japanese Patent Application no. 2019-005811 regarding 177-Lu Labeled peptide conjugate for site specific uPAR-targeting will be granted.

This patent application relates to Curasight’s therapeutic technology uTREAT® and uses thereof. More specifically the invention relates to human uPAR targeted radionuclide therapy, which enables local irradiation of cancer with almost no irradiation of healthy tissue. Together with uTRACE® the combination is known as uPAR Theranostics – the combination of therapy and diagnostics.

The validation of this Japanese patent application has now been officially confirmed by the Japan Patent Office. For Curasight this is an important milestone in the development of uTREAT® as a therapeutic option in cancer” says CEO Ulrich Krasilnikoff.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60



Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and risk stratification in multiple cancer types.